hopefully close enough to the point it gives some Pharma(s) the feeling/need that it's time to take full control of this ship.

I don't see it.

The "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)" breast cancer Phase II study (N=49) runs until next year.

The "Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol" prostate cancer Phase II study (N=40) continues until late next year.

The "ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer" prostate cancer Phase II study (N=54) won't end until 2026.

The various CRADAs with the NCI haven't started yet and will run for multiple years.

So I don't see why any Pharma would buy us out until they (at least) see the results of the majority of those studies -- years down the road.  If that's how it's going to go, I'd rather see Zenith sell for an "early bird special" price.  Give me $7 US today and I'll vote yes.